Related Experiment Video

Updated: Jun 29, 2026

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

Application of kushenin on patients with chronic hepatitis C after renal transplantation

Yang Li1, Wu-jun Xue, Ping Fan

  • 1Department of Renal Transplant, Center of Nephropathy, Medical College, Xi'an Jiaotong University, and Department of Rheumatism, The First Affiliated Hospital, Xi'an, 710061, China.

Chinese Journal of Integrative Medicine
|October 15, 2008
PubMed

Insights

Kushenin treatment in chronic hepatitis C patients post-renal transplant showed improved liver function and higher HCV-RNA negative conversion rates. The drug demonstrated safety and efficacy without impacting renal allograft function.

Area of Science:

  • Nephrology
  • Hepatology
  • Pharmacology

Background:

  • Chronic hepatitis C (HCV) is a concern in renal transplant recipients.
  • Evaluating novel treatments for post-transplant hepatitis C is crucial.

Purpose of the Study:

  • To assess the efficacy and safety of kushenin in treating chronic hepatitis C after renal transplantation.
  • To compare kushenin with conventional liver protective agents.

Main Methods:

  • A randomized controlled trial involving 55 patients undergoing renal transplantation.
  • Patients received either kushenin or conventional agents for 3 months alongside standard immunosuppression.
  • Key outcomes included hepatitis incidence, rejection rates, liver/kidney function markers, fibrosis index, and HCV-RNA levels.

Main Results:

  • Kushenin treatment led to significantly lower levels of liver enzymes (ALT, DBIL) and fibrosis markers (HA, PC III, LN, Col IV) post-transplant.
  • The negative conversion rate of HCV-RNA was significantly higher in the kushenin group (31.03%) compared to controls (11.54%).
  • No significant differences in serious hepatitis incidence, acute rejection rates, or renal function (SCr, CCr) were observed between groups.

Conclusions:

  • Kushenin effectively inhibits HCV proliferation, protects liver cells, and reduces liver fibrosis in renal transplant patients.
  • The drug exhibits a favorable safety profile, with no adverse effects on renal allograft function.
  • Kushenin is a clinically safe and effective option for managing chronic hepatitis C in this patient population.
Abstract

Related Concept Videos

Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...